<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03698448</url>
  </required_header>
  <id_info>
    <org_study_id>3372</org_study_id>
    <secondary_id>2018-000378-30</secondary_id>
    <nct_id>NCT03698448</nct_id>
  </id_info>
  <brief_title>A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis</brief_title>
  <acronym>SMR3372</acronym>
  <official_title>A Randomized, Double Blind, Dose-finding Study of Inhaled Oligosaccharide (OligoG) vs Placebo in Patients With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AlgiPharma AS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cystic Fibrosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Cystic Fibrosis Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cystic Fibrosis Europe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AlgiPharma AS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double blind, placebo controlled study. The study has two parts:&#xD;
&#xD;
      Dose-finding part, followed by longer term follow-up (6 months)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1: Randomized, double blind, placebo controlled dose-finding. Patients will be assigned&#xD;
      to 1 of 3 doses OligoG, or to placebo, on top of Standard of Care. Patients will be treated&#xD;
      for 12 weeks, followed by 4 weeks washout.The primary endpoint is relative change in %&#xD;
      predicted FEV1. Secondary endpoints include additional spirometry parameters, exacerbation&#xD;
      rate, Quality of Life, sputum rheology and microbiology, safety laboratory tests and adverse&#xD;
      event reporting.&#xD;
&#xD;
      Part 2: Randomized double-blind 6 -month study, for longer term follow-up of the dose&#xD;
      identified in Part 1. New patients will be recruited in part 2, in addition to patients who&#xD;
      received placebo in Part 1. In addition to the endpoints studied in Part 1, Part 2 will&#xD;
      include Lung Clearance Index (LCI), chest imaging by MRI or CT, and pharmaco-economic&#xD;
      parameters.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">July 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 10, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised, double blind, dose-finding</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo medication with identical appearance to the active drug</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Forced Expiratory Volume in 1 second (FEV1)</measure>
    <time_frame>Change from before to after 12 weeks treatment (Part 1) and 26 weeks (Part 2)</time_frame>
    <description>the amount of air a person can forcefully exhale in one second</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lung Clearance Index (LCI) (Part two only)</measure>
    <time_frame>Change from before to after 26 weeks treatment</time_frame>
    <description>Lung clearance index (LCI) measured by multiple breath washout is a sensitive measure of ventilation inhomogeneity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum culture microbiology</measure>
    <time_frame>Change from before to after 12 weeks treatment (Part 1) and 26 weeks (Part 2)</time_frame>
    <description>Reduction in Pseudomonas Aeruginosa CFU Counts and total counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Exacerbations</measure>
    <time_frame>Change from before to after 12 weeks treatment (Part 1) and 26 weeks (Part 2)</time_frame>
    <description>Acute pulmonary exacerbations</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Placebo DPI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo dry powder for inhalation. OligoG is replaced by lactose. 10 capsules, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose OligoG DPI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>17.5 mg OligoG dry powder for inhalation. 10 capsules, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>medium dose OligoG DPI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>27.5 mg OligoG dry powder for inhalation. 10 capsules, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose OligoG DPI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>37.5 mg OligoG dry powder for inhalation. 10 capsules, BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OligoG Dry powder for inhalation</intervention_name>
    <description>10 capsules Dry Powder for Inhalation, BID</description>
    <arm_group_label>High dose OligoG DPI</arm_group_label>
    <arm_group_label>Low dose OligoG DPI</arm_group_label>
    <arm_group_label>Placebo DPI</arm_group_label>
    <arm_group_label>medium dose OligoG DPI</arm_group_label>
    <other_name>Placebo dry powder for inhalation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of CF&#xD;
&#xD;
          -  FEV1 at screening &gt;40 and &lt; 90% of predicted normal&#xD;
&#xD;
          -  History of PA infection in last 12 m&#xD;
&#xD;
          -  History of antibiotic treatment due tp PA infection (not for eradication) during last&#xD;
             12 m&#xD;
&#xD;
          -  Concomitant inhaled tobramycin, colistin, aztreonam, or levoflaxin (cycled or&#xD;
             continuous)&#xD;
&#xD;
          -  Stable CF disease&#xD;
&#xD;
          -  Willing to remain on stable CF medication (Standard of care)&#xD;
&#xD;
          -  Women of child-bearing potential must habe negative urine pregnany test&#xD;
&#xD;
          -  Males &amp; females must use acceptable contraception&#xD;
&#xD;
          -  Capable of inhaling dry powder&#xD;
&#xD;
          -  willing to sign informed consent&#xD;
&#xD;
          -  willing and able to follow study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of hypertonic saline &gt; twice daily&#xD;
&#xD;
          -  Clinically significant abnormal lab findings, except CRP. In case of high GGT values,&#xD;
             case will be discussed by experts before deciding&#xD;
&#xD;
          -  History of comorbidity that may distort results or cause additional risk&#xD;
&#xD;
          -  pulmonary exacerbation within 28 days prior to randomisation&#xD;
&#xD;
          -  Change in CF therapy within 28 days prior to randomisation&#xD;
&#xD;
          -  Burkholderia spp. finding within 12 m prior to screening&#xD;
&#xD;
          -  pregnant or breast feeding females&#xD;
&#xD;
          -  History of allergic reactions to IMP ingredients, incl milk protein&#xD;
&#xD;
          -  Inability to perform lung function tests according to ATS/ ERS criteria&#xD;
&#xD;
          -  Uncontrolled or unstable diseases that might limit compliance&#xD;
&#xD;
          -  History of, or planned organ transplantation&#xD;
&#xD;
          -  Allergic ABPA in the last 12 months prior to the screening visit&#xD;
&#xD;
          -  Requirement for continuous oxygen supplementation&#xD;
&#xD;
          -  Current participation in another clinical study&#xD;
&#xD;
          -  medical condition, other than CFwhich exposes the patient to an unacceptably high risk&#xD;
&#xD;
          -  Concurrent mlignant disease, except BCC and cervical neoplasia&#xD;
&#xD;
          -  Clinically significant alcohol or drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silke van Koningsbruggen-Rietschel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Cologne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hilde Morris, DVM</last_name>
    <phone>+4792298921</phone>
    <email>hilde.morris@algipharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne M Graver, MSc</last_name>
    <phone>+4793041021</phone>
    <email>anne.graver@algipharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CF Zentrum Köln, Universitätskrankenhaus Köln</name>
      <address>
        <city>Cologne</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 3, 2018</study_first_submitted>
  <study_first_submitted_qc>October 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oligosaccharide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

